Eterna Therapeutics Inc.
ERNA
$-0.06
Change (1 day)
$2.63
Year High
$0.84
Year Low
Categories
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Eterna Therapeutics Inc. (ERNA) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 425 K | 34.27 M | 46.9 M | 49.13 M | 9.6 M |
| 2022 | 951 K | -7,308,000 | 10.17 M | 22.28 M | 13.68 M |
| 2021 | 684 K | -14,262,000 | 25.93 M | 32.43 M | 18.77 M |
| 2020 | 1.27 M | 5.25 M | 12.91 M | 1.73 M | |
| 2019 | 1.2 M | 2.82 M | 10.19 M | 15.28 M | 6.07 M |